Opportunities for pharmacists in vaccinating higher-risk populations

Public Health Agency of Canada (PHAC). Canadian immunization guide: part 3—vaccination of specific populations. September 1, 2016. Available: www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations.html (accessed Apr. 17, 2019).

Shea KM Edelsberg J Weycker D , et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis 2014;1(1):ofu024.

Doherty M Schmidt-Ott R Santos JI , et al. Vaccination of special populations: protecting the vulnerable. Vaccine 2016;34(52):6681-90.

Ferreira I Isenberg D . Vaccines and biologics. Ann Rheum Dis 2014;73(8):1446-54.

Whiskin C Haaland D Bensen W Brown V . A call to action for adult vaccination: immunocompromised patients at increased risk. Can Rheumatol Assoc J 2014;24(1):10-3a.

Whiskin Consulting. Adult Vaccination Checklist. Hamilton & District Pharmacists’ Association; 2018. Hamilton, Ontario.

Public Health Agency of Canada (PHAC). Canadian immunization guide: part 3—vaccination of specific populations, immunization of adults. February 21, 2018. Available: www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-2-immunization-of-adults.html (accessed Apr. 16, 2019).

Haq K McElhaney JE . Immunosenescence: influenza vaccination and the elderly. Curr Opinion Immunol 2014;29:38-42.

Public Health Agency of Canada (PHAC). Vaccine uptake in Canadian adults: highlights from the 2016 adult National Immunization Coverage Survey (aNICS). March 6, 2019. Available: www.canada.ca/en/services/health/publications/healthy-living/2016-vaccine-uptake-canadian-adults-survey.html (accessed Apr. 1, 2019).

Liu XC Simmonds KA Russell ML Svenson LW . Herpes zoster vaccine (HZV): utilization and coverage 2009-2013, Alberta, Canada. BMC Public Health 2014;14:1098.

Vaudry W Zhao L Stirling R , on behalf of the National Advisory Committee on Immunization (NACI). Summary of the NACI Seasonal Influenza Vaccine Statement for 2018-2019. Can Commun Dis Rep 2018;44(6):123-8. Available: www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2018-44/issue-6-june-7-2018/article-1-summary-influenza-2018-2019.html (accessed Apr. 1, 2019).

Canadian Healthcare Network. Enhancing flu-ency for your 65+ patients. Webinar presentation Slides, September 20, 2018. Available: www.canadianhealthcarenetwork.ca/pharmacists/seniors-health-influenza/learning/webinar-sept-20-enhancing-flu-ency-for-your-65-patients-42683 (accessed Apr. 1, 2019).

McRae C . Canadian Healthcare Network, 2018-2019 flu vaccine programs by province/territory. October 26, 2018. Available: www.canadianhealthcarenetwork.ca/healthcaremanagers/seniors-health-influenza/interactive-map-flu-vaccine-programs-by-province-and-territory-37557 (accessed Apr. 1, 2019).

McElhaney JE Zhou X Talbot HK , et al. The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine 2012;30(12):2060-7.

Kwong JC Schwartz KL Campitelli MA , et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med 2018;378(4):345-53.

National Advisory Committee on Immunization (NACI). Update on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older—Interim Recommendation. October 2016. Available: https://www.canada.ca/en/public-health/services/publications/healthy-living/update-use-of-13-valent-pneumococcal-conjugate-vaccine-pneu-c-13-in-addition-to-23-valent-pneumococcal-polysaccharide-vaccine-pneu-p-23-immunocompetent-adults-65-years-and-older-interim-recommendation.html (accessed Sept. 19, 2019).

Public Health Agency of Canada (PHAC). Canadian immunization guide: part 3—vaccination of specific populations, immunization of immunocompromised persons. May 2018. Available: www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-8-immunization-immunocompromised-persons.html (accessed Apr. 1, 2019).

Papp KA Haraoui B Kumar D , et al. Vaccination guidelines for patients with immune-mediated disorders taking immunosuppressive therapies: executive summary. J Rheumatol 2019;46(7):751-4.

Lee DH Boyle SM Malat G Sharma A Bias T Doyle AM . Low rates of vaccination in listed kidney transplant candidates. Transplant Infect Dis 2016;18(1):155-9.

Robertson CA DiazGranados CA Decker MD Chit A Mercer M Greenberg DP . Fluzone(R) high-dose influenza vaccine. Exp Rev Vaccines 2016;15(12):1495-505.

Colmegna I . Efficacy of high-dose versus standard-dose influenza vaccine in seropositive rheumatoid arthritis patients. Abstract 837, American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting 2018, October 20-24, 2018, Chicago. Available: https://acr.confex.com/acr/2018/meetingapp.cgi/Person/60160 (accessed Apr. 1, 2019).

Park JK Lee YJ Shin K , et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 2018;77(6):898-904.

National Advisory Committee on Immunization (NACI). Statement on the use of conjugate pneumococcal vaccine–13 valent in adults (Pneu-C-13). Can Communicable Dis Rep 2013;39:ACS-5.

National Advisory Committee on Immunization (NACI). Updated recommendations on the use of herpes zoster vaccines. August 30, 2018. Available: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html (accessed Sept. 19, 2019).

Yanni EA Ferreira G Guennec M , et al. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012. BMJ Open 2018;8(6):e020528.

Charlton A . Vaccines and immune modifying/immunosuppressant agents: common questions and answers. University of Alberta PharmD Research. November 2018. Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary.

Alberta Rheumatology. Vaccinations when taking DMARDs or biologics, 2019. Available: https://albertarheumatology.com/vaccinations/ (accessed Apr. 16, 2019).

Papp KA Haraoui B Kumar D , et al. Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. J Cutan Med Surg 2019;23(1):50-74.

Public Health Agency of Canada (PHAC). Seasonal influenza vaccine coverage in Canada, 2017-2018, January 2019. Available: http://publications.gc.ca/collections/collection_2019/aspc-phac/HP40-198-2018-eng.pdf (accessed Apr. 16, 2019).

Husein N Chetty A . 2018 Clinical practice guidelines: influenza, pneumococcal, hepatitis B and herpes zoster vaccinations. Can J Diabetes 2018;42(suppl 1):S142-S4.

Health Quality Ontario. Quality standards, chronic obstructive pulmonary disease, care in the community for adults. 2018. Available: www.hqontario.ca/Portals/0/documents/evidence/quality-standards/qs-chronic-obstructive-pulmonary-disease-quality-standard-en.pdf (accessed Apr. 20, 2019).